Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects

• US 9,867,819 B2
• Filed: 07/10/2017
• Issued: 01/16/2018
• Est. Priority Date: 11/05/2013
• Status: Active Grant

• Current Assignee: Antecip Bioventures II LLC
• Original Assignee: Antecip Bioventures II LLC
• Inventors: Tabuteau, Herriot
• Primary Examiner(s): Baek, Bong-Sook
• Application Number:
  US15/645,939
• Publication Number:
  US 20170304298A1
• Time in Patent Office: 190 Days
• Field of Search: None
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/135 having aromatic rings , e.g. ketamine, nortriptyline methadone A61K31/137
• CPC Class Codes: A61K 31/137 Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
• CPC Class Codes: A61K 31/15 Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
• CPC Class Codes: A61K 31/343 condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
• CPC Class Codes: A61K 31/381 having five-membered rings
• CPC Class Codes: A61K 31/485 Morphinan derivatives, e.g. morphine, codeine
• CPC Class Codes: A61K 9/0053 Mouth and digestive tract, i.e. intraoral and peroral administration rectal administration A61K9/0031

Abstract

This disclosure relates to methods administering various compounds in conjunction with dextromethorphan to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan or dextrorphan and bupropion, hydroxybupropion, erythrohydroxybupropion, threohydroxybupropion, or a metabolite or prodrug of any of these compounds are also disclosed.

Claims

1. A method of correcting extensive metabolism of dextromethorphan in a human subject in need thereof who is not suffering from a cough, comprising co-administering a bupropion and a dextromethorphan to the human subject once a day for at least eight consecutive days or twice a day for at least eight consecutive days, wherein the human subject is an extensive metabolizer of the dextromethorphan in need of treatment with dextromethorphan, and wherein the daily dose of the dextromethorphan is about 40 mg to about 350 mg, and wherein co-administration of the bupropion and the dextromethorphan results in an AUC_0-24 of the dextromethorphan on Day 8 that is at least about 50 ng·

hr/mL, which is at least about 20 times a reference AUC_0-24 of the dextromethorphan on Day 8 that would result from administering the daily dose of the dextromethorphan without the bupropion to the human subject for 8 consecutive days.

2. The method of claim 1, wherein the daily dose of the dextromethorphan is about 60 mg to about 140 mg.

3. The method of claim 1, wherein the daily dose of the dextromethorphan is about 80 mg to about 100 mg.

4. The method of claim 1, wherein a single dose of the dextromethorphan is about 42 mg to about 46 mg.

5. The method of claim 1, wherein a single dose of the dextromethorphan is about 44 mg to about 48 mg.

6. The method of claim 5, wherein the dextromethorphan is deuterated.

7. The method of claim 1, wherein the AUC_0-24 of the dextromethorphan when co-administered with the bupropion is at least about 30 times the reference AUC_0-24 of the dextromethorphan when administered without bupropion.

8. The method of claim 1, wherein the AUC_0-24 of the dextromethorphan when co-administered with the bupropion is at least about 40 times the reference AUC_0-24 of the dextromethorphan when administered without bupropion.

9. The method of claim 5, wherein the AUC_0-24 of the dextromethorphan when co-administered with the bupropion is at least about 50 times the reference AUC_0-24 of the dextromethorphan when administered without bupropion.

10. The method of claim 1, wherein the AUC_0-24 of the dextromethorphan is about 100 ng·

hr/mL to about 200 ng·

hr/mL.

11. The method of claim 1, wherein the AUC_0-24 of the dextromethorphan is about 200 ng·

hr/mL to about 400 ng·

hr/mL.

12. The method of claim 1, wherein the AUC_0-24 of the dextromethorphan is about 400 ng·

hr/mL to about 600 ng·

hr/mL.

13. The method of claim 5, wherein the AUC_0-24 of the dextromethorphan is about 600 ng·

hr/mL to about 800 ng·

hr/mL.

14. The method of claim 1, wherein the AUC_0-24 of the dextromethorphan is about 800 ng·

hr/mL to about 1000 ng·

hr/mL.

15. The method of claim 1, wherein the AUC_0-24 of the dextromethorphan is at least about 1000 ng·

hr/mL.

16. The method of claim 1, wherein the daily dose of the bupropion is about 50 mg to about 300 mg.

17. The method of claim 1, wherein the daily dose of the bupropion is about 70 mg to about 220 mg.

18. The method of claim 1, wherein a single dose of the bupropion is about 95 mg to about 100 mg.

19. The method of claim 5, wherein a single dose of the bupropion is about 100 mg to about 110 mg.

20. The method of claim 1, wherein the bupropion is deuterated.

21. The method of claim 1, wherein the bupropion and the dextromethorphan, are co-administered as a solid or liquid, in a single oral dosage form.

22. The method of claim 21, wherein the single oral dosage form is a solid.

23. The method of claim 22, wherein the single solid oral dosage form further comprises a binder, a disintegrating agent or a lubricant.

24. The method of claim 22, wherein the single solid oral dosage form is a tablet, a troche, a pill or a capsule.

25. The method of claim 21, wherein the single oral dosage form is a liquid.

26. The method of claim 25, wherein the single liquid oral dosage form comprises a liquid or a solid phase dispersion of the bupropion or the dextromethorphan.

27. The method of claim 25, wherein the single liquid oral dosage form comprises a liquid or a solid phase dispersion of the bupropion and the dextromethorphan.

28. The method of claim 12, wherein the bupropion and the dextromethorphan are co-administered to the human subject once a day for at least 30 consecutive days or twice a day for at least 30 consecutive days.

29. The method of claim 1, wherein the bupropion and the dextromethorphan are co-administered to the human subject once a day for at least 60 consecutive days or twice a day for at least 60 consecutive days.